Pharma BD Deal Intelligence
Iclusig delivered a modest, durable hematology franchise, but brigatinib—the $5.2B deal's real thesis with $1B+ peak-sales projections—was crushed by Alecensa in ALK-positive lung cancer, generating only $100-150M annually and leaving Takeda's return far short of the price paid.
Iclusig became a durable niche hematology earner, but brigatinib (Alunbrig) — the deal's real thesis at $1B+ peak-sales projection — was crushed by Alecensa and never came close, leaving a weak return on the $5.2B price.
Full analysis, sources & comparables →Takeda's $5.2B Ariad bid, announced at JPMorgan, signals an aggressive oncology buildout — pairing marketed Iclusig with near-term launch asset brigatinib.
Takeda projected the acquisition would be accretive to Underlying Core Earnings by FY2018, framing the deal as a strategic expansion of its global oncology and…
Morgan Stanley MUFG analyst Shinichiro Muraoka cautioned that Iclusig and brigatinib sit in the 'third-fourth order groups' of their respective markets and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Takeda agreed to acquire ARIAD for $24.00/share in cash, an enterprise value of approximately $5.2B representing a ~75% premium. The deal expanded Takeda's oncology and hematology business with two targeted therapies: marketed Iclusig in CML and Phase 3 brigatinib in NSCLC. Acquisition completed February 16, 2017.
Iclusig became a durable niche hematology earner, but brigatinib (Alunbrig) — the deal's real thesis at $1B+ peak-sales projection — was crushed by Alecensa and never came close, leaving a weak return on the $5.2B price.
Assessment window: 5yr post-close.
9K US cases/yr
Chronic myeloid leukemia (CML) is a hematologic malignancy driven by the BCR-ABL fusion gene (Philadelphia chromosome). Tyrosine kinase inhibitors (TKIs) have transformed CML into a chronic, manageable condition for most patients, but a subset develop resistance — particularly through the T315I gatekeeper mutation — leaving them with limited therapeutic options.
The CML TKI market is anchored by first-line standard-of-care imatinib (Gleevec, Novartis) and second-generation agents dasatinib (Sprycel, BMS) and nilotinib (Tasigna, Novartis). Iclusig (ponatinib) is the only TKI with proven activity against the T315I gatekeeper mutation, validated in the Phase II PACE trial in which 70% of T315I-positive chronic-phase CML patients achieved a major cytogenetic response. Bosulif (bosutinib, Pfizer) competes in the resistant/intolerant setting but lacks T315I activity. Iclusig has carried a black-box warning for arterial occlusive events since 2013, restricting first-line use and capping commercial potential — ARIAD guided 2016 Iclusig revenue at $170-180M. Takeda's acquisition gives it a defensible niche asset in resistant CML with limited near-term competition; the strategic value lies less in displacing front-line TKIs than in owning the only T315I-active option, plus the late-stage ALK pipeline asset brigatinib.
9K US cases/yr
ALK-positive NSCLC is a molecularly defined subset of non-small cell lung cancer driven by anaplastic lymphoma kinase gene rearrangements, found in roughly 3-5% of NSCLC cases and enriched in younger, never- or light-smoker patients. Targeted ALK inhibitors have largely supplanted chemotherapy in this population, but acquired resistance and CNS progression remain critical unmet needs.
At deal time (January 2017), the ALK inhibitor market was led by first-generation crizotinib (Xalkori, Pfizer) and second-generation ceritinib (Zykadia, Novartis) and alectinib (Alecensa, Roche). Brigatinib was under FDA priority review and analysts called it a potential best-in-class second-generation ALK inhibitor with strong activity against crizotinib-refractory disease and CNS metastases — SunTrust analyst Yatin Suneja called brigatinib a 'likely best-in-class ALK+ inhibitor' projected to win FDA approval by April 2017. Brigatinib received accelerated FDA approval as Alunbrig in April 2017 for crizotinib-refractory ALK+ NSCLC. The asset competes head-to-head with alectinib in the post-crizotinib setting, with later entrants lorlatinib (Pfizer) targeting the same niche. Takeda projected combined Iclusig + brigatinib peak US sales of $2B over the following decade, positioning brigatinib as the primary growth engine of the ARIAD acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals (this deal) | 2017 | $5.2B | 47 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2017 deals · Takeda Pharmaceutical Company Ltd. deals · Hematology deals